HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer

Epidermal growth factor-related peptides and their receptors in human malignancies.

Salomon, D., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical reviews in oncology/hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,860 · see citing works

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · see citing works

EGFR Antagonists in Cancer Treatment

Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548 · see citing works

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436 · see citing works

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth

Normanno, N., Campiglio, M., Luca, A. D., Somenzi, G., Maiello, M. R., Ciardiello, F., Gianni, L., Salomon, D. S., & Ménard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273 · see citing works

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

Arteaga, C. L., O’Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., & Davidson, N. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0482 · Cited by 79 · see citing works

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Normanno, N., Campiglio, M., Maiello, M. R., Luca, A. D., Mancino, M., Gallo, M., D’Alessio, A., & Ménard, S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9830-2 · Cited by 51 · see citing works

Pharmacologic resistance in colorectal cancer: a review

Hammond, W. A., Swaika, A., & Mody, K. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 520 · see citing works

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319 · see citing works

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies

Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246 · see citing works

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150 · see citing works

IMGT® databases, related tools and web resources through three main axes of research and development

Manso, T., Folch, G., Giudicelli, V., Jabado-Michaloud, J., Kushwaha, A., Ngoune, V. N., Georga, M., Papadaki, A., Debbagh, C., Pégorier, P., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1136 · Cited by 124 · see citing works

Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121 · see citing works

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119 · see citing works

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Ciardiello, F., Normanno, N., Martinelli, E., Troiani, T., Pisconti, S., Cardone, C., Nappi, A., Bordonaro, R., Rachiglio, A. M., Lambiase, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw136 · Cited by 94 · see citing works

Antibody variable region engineering for improving cancer immunotherapy

Lou, H., & Cao, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12330 · Cited by 75 · see citing works

Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?

Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 58 · see citing works

The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53 · see citing works

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors

Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 52 · see citing works

The clinical significance of HER2 expression in DCIS

Ακρίδα, Ι., & Mulita, F. (2022) · Medical Oncology · doi:10.1007/s12032-022-01876-9 · Cited by 50 · see citing works

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

Wang, G., He, Y., Sun, Y., Wang, W., Qian, X., Yu, X., & Pan, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02213-9 · Cited by 44 · see citing works

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer

Corte, C. M. D., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 40 · see citing works

The Potential of panHER Inhibition in Cancer

Wang, X., Batty, K., Crowe, P. J., Goldstein, D., & Yang, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00002 · Cited by 40 · see citing works

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Stringer-Reasor, E. M., May, J. E., Olariu, E., Caterinicchia, V., Li, Y., Chen, D., Manna, D. L. D., Rocque, G. B., Vaklavas, C., Falkson, C. I., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01408-9 · Cited by 40 · see citing works

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

Vincenzi, B., Cremolini, C., Bianchi, A. S., Russo, A. D., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5231 · Cited by 36 · see citing works

Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32 · see citing works

Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody

Adua, D., Fabio, F. D., Ercolani, G., Fiorentino, M., Gruppioni, E., Altimari, A., Llimpe, F. L. R., Normanno, N., Pinna, A. D., & Pinto, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1270 · Cited by 18 · see citing works

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

Khelwatty, S. A., Puvanenthiran, S., Essapen, S., Bagwan, I., Seddon, A. M., & Modjtahedi, H. (2021) · Cancers · doi:10.3390/cancers13040638 · Cited by 16 · see citing works

HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features

Park, J. S., Yoon, G., Kim, H. J., Park, S. Y., Choi, G., Kang, M. K., Kim, J. G., Jang, J.-S., & Seo, A. N. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2409-y · Cited by 15 · see citing works

Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells

Huang, F., Liang, X., Min, X., Zhang, Y., Wang, B., Peng, Z., Peng, F., Li, M., Chen, L., & Chen, Y. (2019) · Journal of Cancer · doi:10.7150/jca.29327 · Cited by 13 · see citing works

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

Menéndez, J. A. (2012) · Oncology Reports · doi:10.3892/or.2012.1732 · Cited by 9 · see citing works

Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a retrospective study using whole – tissue sections

Kılıçarslan, A., Doğan, H. T., Süngü, N., Doğan, M., Yalçin, S., & Dede, D. Ş. (2018) · Polish Journal of Pathology · doi:10.5114/pjp.2018.75671 · Cited by 9 · see citing works

RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine

Valentini, A. M., Cavalcanti, E., Maggio, M. D., & Caruso, M. L. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000475 · Cited by 8 · see citing works

Clinical Trial Outcomes

Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8 · see citing works

Clinical Actionability of Genes in Gastrointestinal Tumors

Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7 · see citing works

Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines

Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4337 · Cited by 6 · see citing works

The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer

Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2 · see citing works

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients

Pastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 2 · see citing works

HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.63 · Cited by 1 · see citing works

Animal Models of Metastasis

Cochrane, D. R., Lin, D., Dellaire, G., Halvorsen, E. C., Berman, J. N., Wang, Y., Huntsman, D. D., & Bennewith, K. L. (2014) · Cancer metastasis · doi:10.1007/978-3-319-12136-9_5

“Are There New Chemotherapy Drugs Behind the Corner?”

Gambardella, V., Tarazona, N., Huerta, M., & Cervantes, A. M. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-43217-5_45

Additional file 3 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Stringer-Reasor, E. M., May, J. E., Olariu, E., Caterinicchia, V., Li, Y., Chen, D., Della Manna, D. L., Rocque, G. B., Vaklavas, C., Falkson, C. I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14168149

Additional file 1 of An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Stringer-Reasor, E. M., May, J. E., Olariu, E., Caterinicchia, V., Li, Y., Chen, D., Della Manna, D. L., Rocque, G. B., Vaklavas, C., Falkson, C. I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14168143

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works

Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer

Zhang, R., Su, C., Jia, Y.-L., Xing, M., Jin, S., & Zong, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117363 · Cited by 14 · see citing works

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 69 · see citing works

Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies.

Barbara, C., Martin, V., Molinari, F., Landi, L. M., Riva, A., Saletti, P., Dosso, S. D., Geva, R., Tejpar, S., Fountzilas, G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.474 · Cited by 7 · see citing works

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · see citing works